164 related articles for article (PubMed ID: 22435404)
1. Sonoclot® evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs.
Babski DM; Brainard BM; Ralph AG; Pittman JR; Koenig A
J Vet Intern Med; 2012; 26(3):631-8. PubMed ID: 22435404
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
Diquélou A; Barbaste C; Gabaig AM; Trumel C; Abella-Bourges N; Guelfi JF; Bousquet Mélou A
Vet Clin Pathol; 2005 Sep; 34(3):237-42. PubMed ID: 16134071
[TBL] [Abstract][Full Text] [Related]
3. Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs.
McLaughlin CM; Marks SL; Dorman DC; Motsinger-Reif A; Hanel RM
J Vet Emerg Crit Care (San Antonio); 2017 Jan; 27(1):71-81. PubMed ID: 27732770
[TBL] [Abstract][Full Text] [Related]
4. Use of viscoelastic coagulation testing to monitor low molecular weight heparin administration to healthy horses.
Tennent-Brown BS; Epstein KL; Whelchel DD; Giguère S
J Vet Emerg Crit Care (San Antonio); 2013; 23(3):291-9. PubMed ID: 23656212
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
Brooks MB
Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
[TBL] [Abstract][Full Text] [Related]
6. The effect of unfractionated heparin on thrombelastographic analysis in healthy dogs.
Pittman JR; Koenig A; Brainard BM
J Vet Emerg Crit Care (San Antonio); 2010 Apr; 20(2):216-23. PubMed ID: 20487249
[TBL] [Abstract][Full Text] [Related]
7. Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs.
Brainard BM; Koenig A; Babski DM; Blong AE; Scherk JR
Am J Vet Res; 2012 Oct; 73(10):1577-82. PubMed ID: 23013183
[TBL] [Abstract][Full Text] [Related]
8. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis.
Scott KC; Hansen BD; DeFrancesco TC
J Vet Emerg Crit Care (San Antonio); 2009 Feb; 19(1):74-80. PubMed ID: 19691587
[TBL] [Abstract][Full Text] [Related]
9. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
[TBL] [Abstract][Full Text] [Related]
10. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
11. Activated coagulation time in monitoring heparinized dogs.
Green RA
Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
[TBL] [Abstract][Full Text] [Related]
12. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a point-of-care coagulation analyzer (Abaxis VSPro) for identification of coagulopathies in dogs.
Dixon-Jimenez AC; Brainard BM; Cathcart CJ; Koenig A
J Vet Emerg Crit Care (San Antonio); 2013; 23(4):402-7. PubMed ID: 23796019
[TBL] [Abstract][Full Text] [Related]
14. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
15. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
16. Sonoclot evaluation of whole blood coagulation in healthy adult dogs.
Babski DM; Brainard BM; Krimer PM; Ralph AG; Pittman JR; Koenig A
J Vet Emerg Crit Care (San Antonio); 2012 Dec; 22(6):646-52. PubMed ID: 23216839
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®).
Schaden E; Jilch S; Hacker S; Schober A; Kozek-Langenecker S
Clin Chim Acta; 2012 Dec; 414():202-5. PubMed ID: 23041210
[TBL] [Abstract][Full Text] [Related]
18. A dose-response study in animals to evaluate the anticoagulant effect of the stage 2 unfractionated heparin USP monograph change.
Honchel R; Carraway J; Gopee N; Callicott R; Chen J; Patton R; Xu Q; Zalkkar J; Laniyonu A; Krefting I; Cato M; Robie-Suh K; Rieves R
Regul Toxicol Pharmacol; 2011 Aug; 60(3):318-22. PubMed ID: 21549797
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
20. Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation.
Prakash S; Wiersema UF; Bihari S; Roxby D
Anaesth Intensive Care; 2016 Jan; 44(1):85-92. PubMed ID: 26673593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
